Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - HI TECH PHARMACAL CO INCv323045_ex99-1.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

  

FORM 8-K

  

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

  

Date of report (Date of earliest event reported)                September 5, 2012                

 

HI-TECH PHARMACAL CO., INC.
(Exact Name of Registrant as Specified in Its Charter)
 
Delaware
(State or Other Jurisdiction of Incorporation)

 

No. 0-20424 11-2638720
(Commission File Number) (IRS Employer Identification No.)
   
369 Bayview Avenue, Amityville, New York 11701
(Address of Principal Executive Offices) (Zip Code)

 

(631) 789-8228
(Registrant’s Telephone Number, Including Area Code)
 
 
(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 2.02.Results of Operations and Financial Condition.

 

On September 5, 2012 Hi-Tech Pharmacal Co., Inc. (the “Company”) issued a press release announcing its financial results for the fiscal first quarter ended July 31, 2012.

 

A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.

 

The information in Item 2.02 and Item 9.01 shall be deemed to be furnished to the Securities and Exchange Commission but not filed and shall not be deemed incorporated by reference into any filings by the Company under the Securities Act of 1933, as amended, unless the Company expressly states otherwise in such filing.

 

Item 9.01.Financial Statements and Exhibits.

 

(d) Exhibits

 

The following exhibit is furnished herewith:

 

Exhibit NumberDescription

 

Exhibit 99.1Press Release dated September 5, 2012 of Hi-Tech Pharmacal Co., Inc.

  

2
 

 

SIGNATURES

  

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date:  September 5, 2012 HI-TECH PHARMACAL CO., INC.  
       
       
  /s/ David S. Seltzer  
  Name:  David S. Seltzer  
  Title: President and Chief Executive Officer  

 

3
 

 

INDEX TO EXHIBITS

  

Exhibit Number Description
   
99.1 Press Release dated September 5, 2012 of Hi-Tech Pharmacal Co., Inc.

  

4